Q3 2025 United Therapeutics Corp Earnings Call Transcript

Oct 29, 2025 / 01:00PM GMT

Release Date Price: R$113.63

Transcript 8-K10-Q

Key Points

Positve

United Therapeutics Corp (UTHR) reported record total revenues of $800 million for the quarter, representing a 7% growth from the previous year.
The company fully enrolled three Phase III trials and shared promising unblinded results for pulmonary fibrosis, marking the best results ever reported for the condition.
UTHR's Tyvaso DPI platform is driving a shift in treprostinil dosing behavior, with plans to launch an 80-microgram cartridge to enhance patient convenience.
The company has secured multiple favorable coverage decisions with major payers, validating Tyvaso DPI's strong market positioning.
UTHR is guiding towards a $4 billion revenue run rate by 2027, indicating strong future growth potential.

Negative

Despite the positive results, there remains skepticism in the market about the antifibrotic effects of treprostinil in pulmonary fibrosis.
The company faces competition from other products like Yutrepia, although it claims no material impact on its sales.
The full impact of the TETON 2 study results on IPF patient diagnosis and treatment patterns is still uncertain.
There is a reliance on the U.S. market for the majority of revenues, which could pose risks if market dynamics change.
The timeline for regulatory approval and market entry for new products like Ralinepag remains uncertain, with potential delays in the pipeline.

Operator

Good morning, everyone, and welcome to the United Therapeutics Corporation third quarter 2025 corporate update. My name is Jamie, and I will be your conference operator today. (Operator Instructions) Please also note today's event is being recorded.

At this time, I'd like to turn the floor over to Harrison Silvers, Investor Relations Manager at United Therapeutics.

Harrison Silvers

United Therapeutics Corporation - Manager of Investor Relations

Thank you, Jamie. Good morning. It is my pleasure to welcome you to the United Therapeutics Corporation third quarter 2025 corporate update webcast.

Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Forms 10-K and 10-Q, contain additional information on these risks and uncertainties. We assume no obligation to update forward-looking statements.

Today's remarks may discuss the progress and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.